1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Rivus Gets A Muscle-Sparing Heart Failure Hit

 
• By Elizabeth Cairns

But competing with the likes of Wegovy and Zepbound will be a big ask.

Arm muscle tape measure

While incretin drugs work nicely in a variety of metabolic disorders, many experts inside and outside the biopharma industry are exercised about one of their apparent drawbacks: the risk of loss of muscle tissue.

Key Takeaways
  • Rivus Pharmaceuticals’ HU6 succeeded in a mid-stage trial in obesity-related heart failure with preserved ejection fraction.
  • The product is believed to allow significant weight loss without the muscle wasting that is seen with existing drugs

One of the companies aiming to avoid this is Rivus Pharmaceuticals, whose HU6 has hit in a mid-stage trial in obesity-related heart failure with preserved ejection fraction (HFpEF)

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D